Search

Your search keyword '"Mairinger, Severin"' showing total 269 results
Start Over Author "Mairinger, Severin"
269 results on '"Mairinger, Severin"'

8. First-in-human evaluation of 6-bromo-7-[11C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues.

Author

Mairinger, Severin, Jackwerth, Matthias, Chalampalakis, Zacharias, Rausch, Ivo, Weber, Maria, Wölfl-Duchek, Michael, Pracher, Lena, Nics, Lukas, Pahnke, Jens, Langsteger, Werner, Hacker, Marcus, Zeitlinger, Markus, and Langer, Oliver

Abstract

Purpose: Multidrug resistance-associated protein 1 (MRP1) is a transport protein with a widespread tissue distribution, which has been implicated in the pathophysiology of Alzheimer's and chronic respiratory disease. PET with 6-bromo-7-[11C]methylpurine ([11C]BMP) has been used to measure MRP1 function in rodents. In this study, [11C]BMP was for the first time characterised in humans to assess the function of MRP1 and other MRP subtypes in different tissues. Methods: Thirteen healthy volunteers (7 men, 6 women) underwent dynamic whole-body PET scans on a long axial field-of-view (LAFOV) PET/CT system after intravenous injection of [11C]BMP. Three subjects of each sex were scanned a second time to assess reproducibility. Volumes of interest were outlined for MRP-expressing tissues (cerebral cortex, cerebellum, choroid plexus, retina, lungs, myocardium, kidneys, and liver). From the time-activity curves, the elimination rate constant (kE, h− 1) was derived as a parameter for tissue MRP function and its test-retest variability (TRTV, %) was calculated. Radiation dosimetry was calculated using the Medical Internal Radiation Dose (MIRD) methodology. Results: Mean kE and corresponding TRTV values were: cerebral cortex: 0.055 ± 0.010 h− 1 (− 4 ± 24%), cerebellum: 0.033 ± 0.009 h− 1 (1 ± 39%), choroid plexus: 0.292 ± 0.059 h− 1 (0.1 ± 16%), retina: 0.234 ± 0.045 h− 1 (30 ± 38%), lungs: 0.875 ± 0.095 h− 1 (− 3 ± 11%), myocardium: 0.641 ± 0.105 h− 1 (11 ± 25%), kidneys: 1.378 ± 0.266 h− 1 (14 ± 16%), and liver: 0.685 ± 0.072 h− 1 (7 ± 9%). Significant sex differences were found for kE in the cerebellum, lungs and kidneys. Effective dose was 4.67 ± 0.18 µSv/MBq for men and 4.55 ± 0.18 µSv/MBq for women. Conclusion: LAFOV PET/CT with [11C]BMP potentially allows for simultaneous assessment of MRP function in multiple human tissues. Mean TRTV of kE in different tissues was in an acceptable range, except for the retina. The radiation dosimetry of [11C]BMP was in the typical range of 11C-tracers. LAFOV PET/CT holds great potential to assess at a whole-body, multi-tissue level molecular targets relevant for drug disposition in humans. Trial registration: EudraCT 2021-006348-29. Registered 15 December 2021. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. [11C]Metoclopramide PET can detect a seizure-induced up-regulation of cerebral P-glycoprotein in epilepsy patients.

Author

Biali, Myriam El, Breuil, Louise, Jackwerth, Matthias, Mairinger, Severin, Weber, Maria, Wölfl-Duchek, Michael, Bamminger, Karsten, Rausch, Ivo, Nics, Lukas, Hacker, Marcus, Rodrigo, Sebastian, Bouilleret, Viviane, Zeitlinger, Markus, Pataraia, Ekaterina, Tournier, Nicolas, Bauer, Martin, and Langer, Oliver

Subjects
TEMPORAL lobe, POSITRON emission tomography, TEMPORAL lobe epilepsy, BRAIN diseases, CHOROID plexus
Abstract

Background: P-glycoprotein (P-gp) is an efflux transporter which is abundantly expressed at the blood-brain barrier (BBB) and which has been implicated in the pathophysiology of various brain diseases. The radiolabelled antiemetic drug [11C]metoclopramide is a P-gp substrate for positron emission tomography (PET) imaging of P-gp function at the BBB. To assess whether [11C]metoclopramide can detect increased P-gp function in the human brain, we employed drug-resistant temporal lobe epilepsy (TLE) as a model disease with a well characterised, regional P-gp up-regulation at the BBB. Methods: Eight patients with drug-resistant (DRE) TLE, 5 seizure-free patients with drug-sensitive (DSE) focal epilepsy, and 15 healthy subjects underwent brain PET imaging with [11C]metoclopramide on a fully-integrated PET/MRI system. Concurrent with PET, arterial blood sampling was performed to generate a metabolite-corrected arterial plasma input function for kinetic modelling. The choroid plexus was outmasked on the PET images to remove signal contamination from the neighbouring hippocampus. Using a brain atlas, 10 temporal lobe sub-regions were defined and analysed with a 1-tissue-2-rate constant compartmental model to estimate the rate constants for radiotracer transfer from plasma to brain (K1) and from brain to plasma (k2), and the total volume of distribution (VT = K1/k2). Results: DRE patients but not DSE patients showed significantly higher k2 values and a trend towards lower VT values in several temporal lobe sub-regions located ipsilateral to the epileptic focus as compared to healthy subjects (k2: hippocampus: +34%, anterior temporal lobe, medial part: +28%, superior temporal gyrus, posterior part: +21%). Conclusions: [11C]Metoclopramide PET can detect a seizure-induced P-gp up-regulation in the epileptic brain. The efflux rate constant k2 seems to be the most sensitive parameter to measure increased P-gp function with [11C]metoclopramide. Our study provides evidence that disease-induced alterations in P-gp expression at the BBB can lead to changes in the distribution of a central nervous system-active drug to the human brain, which could affect the efficacy and/or safety of drugs. [11C]Metoclopramide PET may be used to assess or predict the contribution of increased P-gp function to drug resistance and disease pathophysiology in various brain diseases. Trial registration: EudraCT 2019-003137-42. Registered 28 February 2020. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Performance and Sensitivity of [99mTc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver

Author

Hernández-Lozano, Irene, primary, Leterrier, Sarah, additional, Mairinger, Severin, additional, Stanek, Johann, additional, Zacher, Anna S., additional, Breyer, Lara, additional, Hacker, Marcus, additional, Zeitlinger, Markus, additional, Pahnke, Jens, additional, Tournier, Nicolas, additional, Wanek, Thomas, additional, and Langer, Oliver, additional

Published
2024
Full Text
View/download PDF

17. St. John's wort extract with a high hyperforin content does not induce P‐glycoprotein activity at the human blood–brain barrier.

Author

El Biali, Myriam, Wölfl‐Duchek, Michael, Jackwerth, Matthias, Mairinger, Severin, Weber, Maria, Bamminger, Karsten, Poschner, Stefan, Rausch, Ivo, Schindler, Natalie, Lozano, Irene Hernández, Jäger, Walter, Nics, Lukas, Tournier, Nicolas, Hacker, Marcus, Zeitlinger, Markus, Bauer, Martin, and Langer, Oliver

Subjects
BLOOD-brain barrier, P-glycoprotein, POSITRON emission tomography, CYTOCHROME P-450, CENTRAL nervous system, DRUG interactions
Abstract

St. John's wort (SJW) extract, a herbal medicine with antidepressant effects, is a potent inducer of intestinal and/or hepatic cytochrome P450 (CYP) enzymes and P‐glycoprotein (P‐gp), which can cause clinically relevant drug interactions. It is currently not known whether SJW can also induce P‐gp activity at the human blood–brain barrier (BBB), which may potentially lead to decreased brain exposure and efficacy of certain central nervous system (CNS)‐targeted P‐gp substrate drugs. In this study, we used a combination of positron emission tomography (PET) imaging and cocktail phenotyping to gain a comprehensive picture on the effect of SJW on central and peripheral P‐gp and CYP activities. Before and after treatment of healthy volunteers (n = 10) with SJW extract with a high hyperforin content (3–6%) for 12–19 days (1800 mg/day), the activity of P‐gp at the BBB was assessed by means of PET imaging with the P‐gp substrate [11C]metoclopramide and the activity of peripheral P‐gp and CYPs was assessed by administering a low‐dose phenotyping cocktail (caffeine, omeprazole, dextromethorphan, and midazolam or fexofenadine). SJW significantly increased peripheral P‐gp, CYP3A, and CYP2C19 activity. Conversely, no significant changes in the peripheral metabolism, brain distribution, and P‐gp‐mediated efflux of [11C]metoclopramide across the BBB were observed following the treatment with SJW extract. Our data suggest that SJW does not lead to significant P‐gp induction at the human BBB despite its ability to induce peripheral P‐gp and CYPs. Simultaneous intake of SJW with CNS‐targeted P‐gp substrate drugs is not expected to lead to P‐gp‐mediated drug interactions at the BBB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Advancing 6-bromo-7-[11C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates.

Author

Mairinger, Severin, Jackwerth, Matthias, Soukup, Ondřej, Blaickner, Matthias, Decristoforo, Clemens, Nics, Lukas, Pahnke, Jens, Hacker, Marcus, Zeitlinger, Markus, and Langer, Oliver

Subjects
*MULTIDRUG resistance-associated proteins, *METHYL triflate, *POSITRON emission tomography, *CURRENT good manufacturing practices, *RADIOCHEMICAL purification, *CHEMICAL testing
Abstract

Background: 6-Bromo-7-[11C]methylpurine ([11C]BMP) is a radiotracer for positron emission tomography (PET) to measure multidrug resistance-associated protein 1 (MRP1) transport activity in different tissues. Previously reported radiosyntheses of [11C]BMP afforded a mixture of 7- and 9-[11C]methyl regioisomers. To prepare for clinical use, we here report an improved regioselective radiosynthesis of [11C]BMP, the results of a non-clinical toxicity study as well as human dosimetry estimates based on mouse PET data. Results: [11C]BMP was synthesised by regioselective N7-methylation of 6-bromo-7H-purine (prepared under good manufacturing practice) with [11C]methyl triflate in presence of 2,2,6,6-tetramethylpiperidine magnesium chloride in a TRACERlab™ FX2 C synthesis module. [11C]BMP was obtained within a total synthesis time of approximately 43 min in a decay-corrected radiochemical yield of 20.5 ± 5.2%, based on starting [11C]methyl iodide, with a radiochemical purity > 99% and a molar activity at end of synthesis of 197 ± 130 GBq/μmol (n = 28). An extended single-dose toxicity study conducted in male and female Wistar rats under good laboratory practice after single intravenous (i.v.) administration of unlabelled BMP (2 mg/kg body weight) revealed no test item related adverse effects. Human dosimetry estimates, based on dynamic whole-body PET data in female C57BL/6J mice, suggested that an i.v. injected activity amount of 400 MBq of [11C]BMP will deliver an effective dose in the typical range of 11C-labelled radiotracers. Conclusions: [11C]BMP can be produced in sufficient amounts and acceptable quality for clinical use. Data from the non-clinical safety evaluation showed no adverse effects and suggested that the administration of [11C]BMP will be safe and well tolerated in humans. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Functionalization of 68 Ga-Radiolabeled Nanodiamonds with Octreotide Does Not Improve Tumor-Targeting Capabilities.

Author

Wanek, Thomas, Raabe, Marco, Alam, Md Noor A, Filip, Thomas, Stanek, Johann, Loebsch, Mathilde, Laube, Christian, Mairinger, Severin, Weil, Tanja, and Kuntner, Claudia

Subjects
NANODIAMONDS, RADIOACTIVE tracers, NANOPARTICLES, IN vivo studies, SPLEEN
Abstract

Nanodiamonds (NDs) are emerging as a novel nanoparticle class with growing interest in medical applications. The surface coating of NDs can be modified by attaching binding ligands or imaging probes, turning them into multi-modal targeting agents. In this investigation, we assessed the targeting efficacy of octreotide-functionalized 68Ga-radiolabelled NDs for cancer imaging and compared it with the tumor uptake using [68Ga]Ga-DOTA-TOC. In vivo studies in mice bearing AR42J tumors demonstrated the highest accumulation of the radiolabeled functionalized NDs in the liver and spleen, with relatively low tumor uptake compared to [68Ga]Ga-DOTA-TOC. Our findings suggest that, within the scope of this study, functionalization did not enhance the tumor-targeting capabilities of NDs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. [11C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier

Author

Mairinger, Severin, primary, Leterrier, Sarah, additional, Filip, Thomas, additional, Löbsch, Mathilde, additional, Pahnke, Jens, additional, Hernández-Lozano, Irene, additional, Stanek, Johann, additional, Tournier, Nicolas, additional, Zeitlinger, Markus, additional, Hacker, Marcus, additional, Langer, Oliver, additional, and Wanek, Thomas, additional

Published
2023
Full Text
View/download PDF

26. [ 11 C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier.

Author

Mairinger, Severin, Leterrier, Sarah, Filip, Thomas, Löbsch, Mathilde, Pahnke, Jens, Hernández-Lozano, Irene, Stanek, Johann, Tournier, Nicolas, Zeitlinger, Markus, Hacker, Marcus, Langer, Oliver, and Wanek, Thomas

Abstract

The efflux transporter P-glycoprotein (P-gp) at the blood-brain barrier limits the cerebral uptake of various xenobiotics. To assess the sensitivity of [11C]metoclopramide to measure decreased cerebral P-gp function, we performed [11C]metoclopramide PET scans without (baseline) and with partial P-gp inhibition by tariquidar in wild-type, heterozygous Abcb1a/b (+/−) and homozygous Abcb1a/b (−/−) mice as models with controlled levels of cerebral P-gp expression. Brains were collected to quantify P-gp expression with immunohistochemistry. Brain uptake of [11C]metoclopramide was expressed as the area under the brain time-activity curve (AUCbrain) and compared with data previously obtained with (R)-[11C]verapamil and [11C] N -desmethyl-loperamide. Abcb1a/b (+/−) mice had intermediate P-gp expression compared to wild-type and Abcb1a/b (−/−) mice. In baseline scans, all three radiotracers were able to discriminate Abcb1a/b (−/−) from wild-type mice (2.5- to 4.6-fold increased AUCbrain, p ≤ 0.0001). However, only [11C]metoclopramide could discriminate Abcb1a/b (+/−) from wild-type mice (1.46-fold increased AUCbrain, p ≤ 0.001). After partial P-gp inhibition, differences in [11C]metoclopramide AUCbrain between Abcb1a/b (+/−) and wild-type mice (1.39-fold, p ≤ 0.001) remained comparable to baseline. There was a negative correlation between baseline [11C]metoclopramide AUCbrain and ex-vivo -measured P-gp immunofluorescence (r = − 0.9875, p ≤ 0.0001). Our data suggest that [11C]metoclopramide is a sensitive radiotracer to measure moderate, but (patho-)physiologically relevant decreases in cerebral P-gp function without the need to co-administer a P-gp inhibitor. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Synthesis and preclinical characterization of 1-(6′-deoxy-6′-[18F]fluoro-β-d-allofuranosyl)-2-nitroimidazole (β-6′-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia

Author

Wanek, Thomas, Kreis, Katharina, Križková, Petra, Schweifer, Anna, Denk, Christoph, Stanek, Johann, Mairinger, Severin, Filip, Thomas, Sauberer, Michael, Edelhofer, Patricia, Traxl, Alexander, Muchitsch, Viktoria E., Mereiter, Kurt, Hammerschmidt, Friedrich, Cass, Carol E., Damaraju, Vijaya L., Langer, Oliver, and Kuntner, Claudia

Published
2016
Full Text
View/download PDF

33. Positron Emission Tomography-Based Pharmacokinetic Analysis To Assess Renal Transporter-Mediated Drug-Drug Interactions of Antimicrobial Drugs

Author

Hernández-Lozano, Irene, primary, Mairinger, Severin, additional, Filip, Thomas, additional, Löbsch, Mathilde, additional, Stanek, Johann, additional, Kuntner, Claudia, additional, Bauer, Martin, additional, Zeitlinger, Markus, additional, Hacker, Marcus, additional, Helbich, Thomas H., additional, Wanek, Thomas, additional, and Langer, Oliver, additional

Published
2023
Full Text
View/download PDF

38. 32nd International Austrian Winter Symposium: Zell am See, the Netherlands. 20-23 January 2016

Author

Langsteger, W, Rezaee, A, Loidl, W, Geinitz, HS, Fitz, F, Steinmair, M, Broinger, G, Pallwien-Prettner, L, Beheshti, M, Imamovic, L, Beheshti, M, Rendl, G, Hackl, D, Tsybrovsky, O, Steinmair, M, Emmanuel, K, Moinfar, F, Pirich, C, Langsteger, W, Bytyqi, A, Karanikas, G, Mayerhöfer, M, Koperek, O, Niederle, B, Hartenbach, M, Beyer, T, Herrmann, K, Czernin, J, Rausch, I, Rust, P, DiFranco, MD, Lassen, M, Stadlbauer, A, Mayerhöfer, ME, Hartenbach, M, Hacker, M, Beyer, T, Binzel, K, Magnussen, R, Wei, W, Knopp, MU, Flanigan, DC, Kaeding, C, Knopp, MV, Leisser, A, Nejabat, M, Hartenbach, M, Kramer, G, Krainer, M, Hacker, M, Haug, A, Lehnert, Wencke, Schmidt, Karl, Kimiaei, Sharok, Bronzel, Marcus, Kluge, Andreas, Wright, CL, Binzel, K, Zhang, J, Wuthrick, Evan, Maniawski, Piotr, Knopp, MV, Blaickner, M, Rados, E, Huber, A, Dulovits, M, Kulkarni, H, Wiessalla, S, Schuchardt, C, Baum, RP, Knäusl, B, Georg, D, Bauer, M, Wulkersdorfer, B, Wadsak, W, Philippe, C, Haslacher, H, Zeitlinger, M, Langer, O, Bauer, M, Feldmann, M, Karch, R, Wadsak, W, Zeitlinger, M, Koepp, MJ, Asselin, M-C, Pataraia, E, Langer, O, Zeilinger, M, Philippe, C, Dumanic, M, Pichler, F, Pilz, J, Hacker, M, Wadsak, W, Mitterhauser, M, Nics, L, Steiner, B, Hacker, M, Mitterhauser, M, Wadsak, W, Traxl, A, Wanek, Thomas, Kryeziu, Kushtrim, Mairinger, Severin, Stanek, Johann, Berger, Walter, Kuntner, Claudia, Langer, Oliver, Mairinger, S, Wanek, T, Traxl, A, Krohn, M, Stanek, J, Filip, T, Sauberer, M, Kuntner, C, Pahnke, J, Langer, O, Svatunek, D, Denk, C, Wilkovitsch, M, Wanek, T, Filip, T, Kuntner-Hannes, C, Fröhlich, J, Mikula, H, Denk, C, Svatunek, D, Wanek, T, Mairinger, S, Stanek, J, Filip, T, Fröhlich, J, Mikula, H, Kuntner-Hannes, C, Balber, T, Singer, J, Fazekas, J, Rami-Mark, C, Berroterán-Infante, N, Jensen-Jarolim, E, Wadsak, W, Hacker, M, Viernstein, H, Mitterhauser, M, Denk, C, Svatunek, D, Sohr, B, Mikula, H, Fröhlich, J, Wanek, T, Kuntner-Hannes, C, Filip, T, Pfaff, S, Philippe, C, Mitterhauser, M, Hartenbach, M, Hacker, M, Wadsak, W, Wanek, T, Halilbasic, E, Visentin, M, Mairinger, S, Stieger, B, Kuntner, C, Trauner, M, Langer, O, Lam, P, Aistleitner, M, Eichinger, R, Artner, C, Eidherr, H, Vraka, C, Haug, A, Mitterhauser, M, Nics, L, Hartenbach, M, Hacker, M, Wadsak, W, Kvaternik, H, Müller, R, Hausberger, D, Zink, C, Aigner, RM, Cossío, U, Asensio, M, Montes, A, Akhtar, S, te Welscher, Y, van Nostrum, R, Gómez-Vallejo, V, Llop, J, VandeVyver, F, Barclay, T, Lippens, N, Troch, M, Hehenwarter, L, Egger, B, Holzmannhofer, J, Rodrigues-Radischat, M, Pirich, C, Pötsch, N, Rausch, I, Wilhelm, D, Weber, M, Furtner, J, Karanikas, G, Wöhrer, A, Mitterhauser, M, Hacker, M, Traub-Weidinger, T, Cassou-Mounat, T, Balogova, S, Nataf, V, Calzada, M, Huchet, V, Kerrou, K, Devaux, J-Y, Mohty, M, Garderet, L, Talbot, J-N, Stanzel, S, Pregartner, G, Schwarz, T, Bjelic-Radisic, V, Liegl-Atzwanger, B, Aigner, R, Stanzel, S, Quehenberger, F, Aigner, RM, Marković, A Koljević, Janković, Milica, Jerković, V Miler, Paskaš, M, Pupić, G, Džodić, R, Popović, D, Fornito, MC, Familiari, D, Koranda, P, Polzerová, H, Metelková, I, Henzlová, L, Formánek, R, Buriánková, E, Kamínek, M, Thomson, WH, Lewis, C, Thomson, WH, O’Brien, J, James, G, Notghi, A, Huber, H, Stelzmüller, I, Wunn, R, Mandl, M, Fellner, F, Lamprecht, B, Gabriel, M, Fornito, MC, Leonardi, G, Thomson, WH, O’Brien, J, James, G, Hudzietzová, J, Sabol, J, and Fülöp, M

Published
2016
Full Text
View/download PDF

39. Use of PET Imaging to Assess the Efficacy of Thiethylperazine to Stimulate Cerebral MRP1 Transport Activity in Wild-Type and APP/PS1-21 Mice

Author

Wölfl-Duchek, Michael, primary, Mairinger, Severin, additional, Hernández-Lozano, Irene, additional, Filip, Thomas, additional, Zoufal, Viktoria, additional, Löbsch, Mathilde, additional, Stanek, Johann, additional, Kuntner, Claudia, additional, Wanek, Thomas, additional, Bauer, Martin, additional, Pahnke, Jens, additional, and Langer, Oliver, additional

Published
2022
Full Text
View/download PDF

43. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [ 11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate

Author

Mairinger, Severin, Langer, Oliver, Kuntner, Claudia, Wanek, Thomas, Bankstahl, Jens P., Bankstahl, Marion, Stanek, Johann, Dörner, Bernd, Bauer, Florian, Baumgartner, Christoph, Löscher, Wolfgang, Erker, Thomas, and Müller, Markus

Published
2010
Full Text
View/download PDF

48. Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [11C]Tariquidar and PET in Humans and Mice

Author

Hernández Lozano, Irene, Bauer, Martin, Wulkersdorfer, Beatrix, Traxl, Alexander, Philippe, Cécile, Weber, Maria, Häusler, Stephanie, Stieger, Bruno, Jäger, Walter, Mairinger, Severin, Wanek, Thomas, Hacker, Marcus, Zeitlinger, Markus, Langer, Oliver, University of Zurich, and Langer, Oliver

Subjects
10199 Clinic for Clinical Pharmacology and Toxicology, 1313 Molecular Medicine, 3002 Drug Discovery, Drug Discovery, 3003 Pharmaceutical Science, Molecular Medicine, Pharmaceutical Science, 610 Medicine & health
Published
2020

49. sj-pdf-1-jcb-10.1177_0271678X20965500 - Supplemental material for Complete inhibition of ABCB1 and ABCG2 at the blood–brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib

Author

Tournier, Nicolas, Goutal, Sebastien, Mairinger, Severin, Lozano, Irene H, Filip, Thomas, Sauberer, Michael, Caillé, Fabien, Breuil, Louise, Stanek, Johann, Freeman, Anna F, Novarino, Gaia, Truillet, Charles, Wanek, Thomas, and Langer, Oliver

Subjects
110320 Radiology and Organ Imaging, FOS: Clinical medicine, FOS: Biological sciences, Medicine, Cell Biology, 110305 Emergency Medicine, 110306 Endocrinology, Biochemistry, 69999 Biological Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-1-jcb-10.1177_0271678X20965500 for Complete inhibition of ABCB1 and ABCG2 at the blood–brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib by Nicolas Tournier, Sebastien Goutal, Severin Mairinger, Irene H Lozano, Thomas Filip, Michael Sauberer, Fabien Caillé, Louise Breuil, Johann Stanek, Anna F Freeman, Gaia Novarino, Charles Truillet, Thomas Wanek and Oliver Langer in Journal of Cerebral Blood Flow & Metabolism

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results